1
|
Gyebrovszki B, Ács A, Szabó D, Auer F, Novozánszki S, Rojkovich B, Magyar A, Hudecz F, Vékey K, Drahos L, Sármay G. The Role of IgG Fc Region N-Glycosylation in the Pathomechanism of Rheumatoid Arthritis. Int J Mol Sci 2022; 23:ijms23105828. [PMID: 35628640 PMCID: PMC9146365 DOI: 10.3390/ijms23105828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 05/18/2022] [Accepted: 05/20/2022] [Indexed: 11/30/2022] Open
Abstract
Anti-citrullinated protein antibodies (ACPAs) are involved in the pathogenesis of rheumatoid arthritis. N-glycosylation pattern of ACPA-IgG and healthy IgG Fc differs. The aim of this study is to determine the relative sialylation and galactosylation level of ACPAs and control IgG to assess their capability of inducing TNFα production, and furthermore, to analyze the correlations between the composition of Fc glycans and inflammatory markers in RA. We isolated IgG from sera of healthy volunteers and RA patients, and purified ACPAs on a citrulline-peptide column. Immunocomplexes (IC) were formed by adding an F(ab)2 fragment of anti-human IgG. U937 cells were used to monitor the binding of IC to FcγR and to trigger TNFα release determined by ELISA. To analyze glycan profiles, control IgG and ACPA-IgG were digested with trypsin and the glycosylation patterns of glycopeptides were analyzed by determining site-specific N-glycosylation using nano-UHPLC-MS/MS. We found that both sialylation and galactosylation levels of ACPA-IgG negatively correlate with inflammation-related parameters such as CRP, ESR, and RF. Functional assays show that dimerized ACPA-IgG significantly enhances TNFα release in an FcγRI-dependent manner, whereas healthy IgG does not. TNFα production inversely correlates with the relative intensities of the G0 glycoform, which lacks galactose and terminal sialic acid moieties.
Collapse
Affiliation(s)
- Balázs Gyebrovszki
- Department of Immunology, Eötvös Loránd University, 1117 Budapest, Hungary; (B.G.); (F.A.); (S.N.)
| | - András Ács
- MS Proteomics Research Group, Research Centre for Natural Sciences, Eötvös Loránd Research Network, 1117 Budapest, Hungary; (A.Á.); (D.S.); (K.V.); (L.D.)
| | - Dániel Szabó
- MS Proteomics Research Group, Research Centre for Natural Sciences, Eötvös Loránd Research Network, 1117 Budapest, Hungary; (A.Á.); (D.S.); (K.V.); (L.D.)
- Hevesy György PhD School of Chemistry, Faculty of Science, Eötvös Loránd University, 1117 Budapest, Hungary
| | - Felícia Auer
- Department of Immunology, Eötvös Loránd University, 1117 Budapest, Hungary; (B.G.); (F.A.); (S.N.)
- Translational Glycomics Research Group, Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, 8200 Veszprém, Hungary
| | - Soma Novozánszki
- Department of Immunology, Eötvös Loránd University, 1117 Budapest, Hungary; (B.G.); (F.A.); (S.N.)
- Central Laboratory-Microbiology Profile, Molecular Department, National Institute of Hematology and Infectious Diseases, Central Hospital of Southern Pest, 1097 Budapest, Hungary
| | - Bernadette Rojkovich
- Rheumatology Department III, Polyclinic of the Hospitaller Brothers of St. John of God, 1027 Budapest, Hungary;
| | - Anna Magyar
- ELKH-ELTE Research Group of Peptide Chemistry, 1117 Budapest, Hungary; (A.M.); (F.H.)
| | - Ferenc Hudecz
- ELKH-ELTE Research Group of Peptide Chemistry, 1117 Budapest, Hungary; (A.M.); (F.H.)
| | - Károly Vékey
- MS Proteomics Research Group, Research Centre for Natural Sciences, Eötvös Loránd Research Network, 1117 Budapest, Hungary; (A.Á.); (D.S.); (K.V.); (L.D.)
| | - László Drahos
- MS Proteomics Research Group, Research Centre for Natural Sciences, Eötvös Loránd Research Network, 1117 Budapest, Hungary; (A.Á.); (D.S.); (K.V.); (L.D.)
| | - Gabriella Sármay
- Department of Immunology, Eötvös Loránd University, 1117 Budapest, Hungary; (B.G.); (F.A.); (S.N.)
- Correspondence:
| |
Collapse
|
2
|
Sun H, Liu J, Xiao P, Zhou Y, Li H, Shen M, Sun K, Wang X, Zhou M, Song D. Epitope mapping of antibodies in C-reactive protein assay kits by hydrogen-deuterium exchange mass spectrometry explains differential results across kits. Anal Bioanal Chem 2022; 414:3875-3884. [PMID: 35389096 DOI: 10.1007/s00216-022-04029-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 03/09/2022] [Accepted: 03/17/2022] [Indexed: 01/08/2023]
Abstract
C-Reactive protein (CRP) is an important marker for in vitro diagnosis (IVD) of inflammation. However, CRP immunoturbidimetric kits from different manufacturers exhibit inconsistency in evaluation, making clinical diagnosis challenging. The use of immunological methods in diagnosis means that the differences in epitopes across kits may directly lead to inconsistent results. Therefore, to provide consistent results, it is essential to perform epitope mapping of different kits. The composition of antibodies in a single kit is typically complex, with a combination of polyclonal antibodies or monoclonal antibodies. Here, we show an epitope screening strategy for complex antibodies in a kit based on hydrogen-deuterium exchange mass spectrometry (HDX-MS). We applied this workflow to successfully map the epitopes for three kits from three different manufacturers and compared their quantitative results. We obtained different quantitative results using kits from different manufacturers upon epitope mapping, confirming the correlation between the quantitative results and the epitopes. Thus, we have established a workflow based on HDX-MS to screen epitopes in IVD kits. This work helps determine the quantitative accuracy of a kit based on structural information, can guide the design and production of IVD reagents, and further improves the accuracy of IVD.
Collapse
Affiliation(s)
- Haofeng Sun
- Division of Chemical Metrology and Analytical Science, National Institute of Metrology, Beijing, 100029, China.,School of Chemical and Engineering, Nanjing University of Science and Technology, Jiangsu, 210094, China
| | - Jianyi Liu
- Division of Chemical Metrology and Analytical Science, National Institute of Metrology, Beijing, 100029, China
| | - Peng Xiao
- Division of Chemical Metrology and Analytical Science, National Institute of Metrology, Beijing, 100029, China
| | - Yi Zhou
- Division of Chemical Metrology and Analytical Science, National Institute of Metrology, Beijing, 100029, China.,School of Chemical Engineering, Beijing University of Chemical Technology, Beijing, 100029, China
| | - Hongmei Li
- Division of Chemical Metrology and Analytical Science, National Institute of Metrology, Beijing, 100029, China
| | - Min Shen
- Reference Laboratory, Medical System Biotechnology Co., Ltd., Ningbo, 315104, China
| | - Keqi Sun
- Reference System Department, Maccura Biotechnology Co., Ltd., Chengdu, 611713, China
| | - Xiaojian Wang
- Reference Laboratory, Beijing Strong Biotechnologies, Inc., Beijing, 101400, Huairou, China
| | - Min Zhou
- School of Chemical and Engineering, Nanjing University of Science and Technology, Jiangsu, 210094, China.
| | - Dewei Song
- Division of Chemical Metrology and Analytical Science, National Institute of Metrology, Beijing, 100029, China.
| |
Collapse
|
4
|
Srivastava S, Chatziefthymiou SD, Kolbe M. Vaccines Targeting Numerous Coronavirus Antigens, Ensuring Broader Global Population Coverage: Multi-epitope and Multi-patch Vaccines. METHODS IN MOLECULAR BIOLOGY (CLIFTON, N.J.) 2021; 2410:149-175. [PMID: 34914046 DOI: 10.1007/978-1-0716-1884-4_7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Coronaviruses are causative agents of different zoonosis including SARS, MERS, or COVID-19 in humans. The high transmission rate of coronaviruses, the time-consuming development of efficient anti-infectives and vaccines, the possible evolutionary adaptation of the virus to conventional vaccines, and the challenge to cover broad human population worldwide are the major reasons that made it challenging to avoid coronaviruses outbreaks. Although, a plethora of different approaches are being followed to design and develop vaccines against coronaviruses, most of them target subunits, full-length single, or only a very limited number of proteins. Vaccine targeting multiple proteins or even the entire proteome of the coronavirus is yet to come. In the present chapter, we will be discussing multi-epitope vaccine (MEV) and multi-patch vaccine (MPV) approaches to design and develop efficient and sustainably successful strategies against coronaviruses. MEV and MPV utilize highly conserved, potentially immunogenic epitopes and antigenic patches, respectively, and hence they have the potential to target large number of coronavirus proteins or even its entire proteome, allowing us to combat the challenge of its evolutionary adaptation. In addition, the large number of human leukocyte antigen (HLA) alleles targeted by the chosen specific epitopes enables MEV and MPV to cover broader global population.
Collapse
Affiliation(s)
- Sukrit Srivastava
- Infection Biology Group, Indian Foundation for Fundamental Research, Raebareli, Uttar Pradesh, India.
| | - Spyros D Chatziefthymiou
- Deutsches Elektronen-Synchrotron (DESY), Hamburg, Germany.,Department of Structural Infection Biology, Center for Structural Systems Biology (CSSB), Helmholtz-Center for Infection Research (HZI), Hamburg, Germany
| | - Michael Kolbe
- Department of Structural Infection Biology, Center for Structural Systems Biology (CSSB), Helmholtz-Center for Infection Research (HZI), Hamburg, Germany. .,MIN-Faculty University Hamburg, Hamburg, Germany.
| |
Collapse
|
5
|
Sabatino D. Medicinal Chemistry and Methodological Advances in the Development of Peptide-Based Vaccines. J Med Chem 2020; 63:14184-14196. [PMID: 32990437 DOI: 10.1021/acs.jmedchem.0c00848] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The evolution of rapidly proliferating infectious and tumorigenic diseases has resulted in an urgent need to develop new and improved intervention strategies. Among the many therapeutic strategies at our disposal, our immune system remains the gold-standard in disease prevention, diagnosis, and treatment. Vaccines have played an important role in eradicating or mitigating the spread of infectious diseases by bolstering our immunity. Despite their utility, the design and development of new, more effective vaccines remains a public health necessity. Peptide-based vaccines have been developed for a wide range of established and emerging infectious and tumorigenic diseases. New innovations in epitope design and selection, synthesis, and formulation as well as screening techniques against immunological targets have led to more effective peptide vaccines. Current and future work is geared toward the translation of peptide vaccines from preclinical to clinical utility.
Collapse
Affiliation(s)
- David Sabatino
- Department of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States
| |
Collapse
|